Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,395 questions in 172 reviews · Gut
current versionsNo studies 420 · 17.5%Ungraded 60 · 2.5%Very low 821 · 34.3%Low 602 · 25.1%Moderate 397 · 16.6%High 95 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings table (subcomparison 6): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention alone Toxicity · palliative participants with SCC of the esophagus Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | no estimate extracted | 2 studies · 150 participants | Very low |
Summary of findings table (subcomparison 6): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention alone Quality of life · palliative participants with SCC of the esophagus Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | no estimate extracted | 1 study · 156 participants | Very low |
Summary of findings table: chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention alone Quality of life · palliative participants with esophageal and GE‐junction carcinoma Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | no estimate extracted | 5 studies · 1870 participants | Very low |
Summary of findings table (sensitivity analysis): interventions esophageal and GE‐junction carcinoma vs gastric carcinoma Studies with gastric cancer participants in addition to eligible participants · palliative participants with esophageal and GE‐junction carcinoma or gastric carcinoma Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | HR 0.94 [0.83, 1.05] | 8 studies · 1755 participants | Ungraded |
Summary of findings table (sensitivity analysis): interventions esophageal and GE‐junction carcinoma vs gastric carcinoma Sensitivity analysis, meta‐regression analysis, first part · palliative participants with esophageal and GE‐junction carcinoma or gastric carcinoma Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | HR 0.75 [0.68, 0.84] | 11 studies · 1347 participants | Very low |
Summary of findings table (sensitivity analysis): interventions esophageal and GE‐junction carcinoma vs gastric carcinoma Sensitivity analysis, only esophageal and GE‐junction cancer participants · palliative participants with esophageal and GE‐junction carcinoma or gastric carcinoma Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | HR 0.66 [0.54, 0.81] | 5 studies · 538 participants | Ungraded |
Summary of findings table (sensitivity analysis): interventions esophageal and GE‐junction carcinoma vs gastric carcinoma Sensitivity analysis, only gastric cancer participants · palliative participants with esophageal and GE‐junction carcinoma or gastric carcinoma Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | HR 0.89 [0.76, 1.04] | 5 studies · 2093 participants | Ungraded |
Summary of findings table (sensitivity analysis): interventions esophageal and GE‐junction carcinoma vs gastric carcinoma Sensitivity analysis, meta‐regression analysis, second part · palliative participants with esophageal and GE‐junction carcinoma or gastric carcinoma Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | HR 0.66 [0.54, 0.81] | 5 studies · 538 participants | Moderate |
Chemotherapy vs best supportive care Overall survival · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.37 [0.24, 0.55] | 3 studies · 184 participants | Moderate |
5‐FU/cisplatin/anthracycline combinations vs 5‐FU/anthracycline combinations (without cisplatin) Overall survival · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.82 [0.73, 0.92] | 7 studies · 1147 participants | Low |
Irinotecan vs non‐irinotecan‐containing regimens Overall survival · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.87 [0.8, 0.95] | 10 studies · 2135 participants | Moderate |
Irinotecan vs non‐irinotecan‐containing regimens Overall survival ‐ Substitutive comparisons · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.87 [0.75, 1] | 6 studies · 826 participants | Moderate |
Irinotecan vs non‐irinotecan‐containing regimens Overall survival ‐ Additive comparisons · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.88 [0.76, 1.03] | 3 studies · 500 participants | Low |
Irinotecan vs non‐irinotecan‐containing regimens Overall survival ‐ Other comparisons · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.87 [0.76, 1] | 2 studies · 809 participants | Very low |
Irinotecan vs non‐irinotecan‐containing regimens Tumour response · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 1.72 [1.24, 2.4] | 10 studies · 1266 participants | Low |
Irinotecan vs non‐irinotecan‐containing regimens Tumour response ‐ Substitutive comparisons · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 1.53 [0.93, 2.5] | 6 studies · 756 participants | Low |
Irinotecan vs non‐irinotecan‐containing regimens Tumour response ‐ Additive comparisons · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 2.18 [1.25, 3.8] | 3 studies · 345 participants | Low |
Irinotecan vs non‐irinotecan‐containing regimens Tumour response ‐ Other comparisons · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 1.87 [0.89, 3.91] | 2 studies · 165 participants | Very low |
Irinotecan vs non‐irinotecan‐containing regimens Progression‐free survival · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.76 [0.69, 0.84] | 7 studies · 1640 participants | High |
Chemotherapy vs best supportive care Time to progression · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.31 [0.22, 0.43] | 2 studies · 144 participants | Moderate |
Irinotecan vs non‐irinotecan‐containing regimens Progression‐free survival ‐ Substitutive comparison · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.85 [0.72, 1] | 5 studies · 741 participants | Moderate |
Irinotecan vs non‐irinotecan‐containing regimens Progression‐free survival ‐ Additive comparisons · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.51 [0.33, 0.77] | 1 study · 90 participants | Moderate |
Irinotecan vs non‐irinotecan‐containing regimens Progression‐free survival ‐ Other comparisons · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.74 [0.66, 0.84] | 2 studies · 809 participants | High |
Irinotecan vs non‐irinotecan‐containing regimens Treatment‐related death · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 0.88 [0.23, 3.32] | 9 studies · 1979 participants | Low |
Irinotecan vs non‐irinotecan‐containing regimens Treatment discontinuation due to toxicity · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 1 [0.46, 2.2] | 9 studies · 1979 participants | Very low |
Docetaxel vs non‐docetaxel‐containing regimens Overall survival · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.86 [0.78, 0.95] | 8 studies · 2001 participants | High |
Docetaxel vs non‐docetaxel‐containing regimens Overall survival ‐ Substitutive comparisons · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 1.05 [0.87, 1.27] | 3 studies · 479 participants | Moderate |
Docetaxel vs non‐docetaxel‐containing regimens Overall survival ‐ Additive comparisons · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.8 [0.71, 0.91] | 4 studies · 1466 participants | Moderate |
Docetaxel vs non‐docetaxel‐containing regimens Overall survival ‐ Other comparisons · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.8 [0.46, 1.39] | 1 study · 56 participants | Very low |
Docetaxel vs non‐docetaxel‐containing regimens Tumour response · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 1.37 [1.03, 1.83] | 9 studies · 1820 participants | Moderate |
Combination vs single‐agent chemotherapy Overall survival · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.84 [0.79, 0.89] | 23 studies · 4447 participants | Moderate |
Docetaxel vs non‐docetaxel‐containing regimens Tumour response ‐ Substitutive comparison · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 1.03 [0.71, 1.5] | 4 studies · 525 participants | Moderate |
Docetaxel vs non‐docetaxel‐containing regimens Tumour response ‐ Additive comparison · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 1.83 [1.45, 2.32] | 4 studies · 1235 participants | High |
Docetaxel vs non‐docetaxel‐containing regimens Tumour response ‐ Other comparison · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 0.33 [0.12, 0.96] | 1 study · 60 participants | Very low |
Docetaxel vs non‐docetaxel‐containing regimens Time to progression · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 1.06 [0.85, 1.32] | 2 studies · 360 participants | Very low |
Docetaxel vs non‐docetaxel‐containing regimens Progression‐free survival · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.76 [0.63, 0.91] | 5 studies · 1498 participants | Moderate |
Docetaxel vs non‐docetaxel‐containing regimens Progression‐free survival ‐ Substitutive comparisons · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 1.15 [0.77, 1.72] | 1 study · 119 participants | Very low |
Docetaxel vs non‐docetaxel‐containing regimens Progression‐free survival ‐ Additive comparison · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.7 [0.61, 0.81] | 3 studies · 1323 participants | High |
Docetaxel vs non‐docetaxel‐containing regimens Progression‐free survival ‐ Other comparison · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.94 [0.55, 1.6] | 1 study · 56 participants | Very low |
Docetaxel vs non‐docetaxel‐containing regimens Treatment‐related death · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 1.1 [0.55, 2.2] | 7 studies · 2113 participants | Moderate |
Docetaxel vs non‐docetaxel‐containing regimens Treatment discontinuation due to toxicity · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 0.81 [0.53, 1.25] | 5 studies · 1066 participants | Low |
Combination vs single‐agent chemotherapy Tumour response · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 2.3 [1.94, 2.72] | 18 studies · 2833 participants | High |
Capecitabine vs 5‐FU‐containing regimens Overall Survival · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.94 [0.79, 1.11] | 5 studies · 732 participants | Moderate |
Capecitabine vs 5‐FU‐containing regimens Tumour response · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 0.85 [0.4, 1.79] | 4 studies · 636 participants | Very low |
Capecitabine vs 5‐FU‐containing regimens Time to progression · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.72 [0.47, 1.12] | 1 study · 85 participants | Very low |
Capecitabine vs 5‐FU‐containing regimens Progression‐free survival · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.98 [0.77, 1.23] | 4 studies · 647 participants | Very low |
Capecitabine vs 5‐FU‐containing regimens Treatment‐related death · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 1.88 [0.23, 15.15] | 2 studies · 481 participants | Very low |
Capecitabine vs 5‐FU‐containing regimens Treatment discontinuation due to toxicity · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 0.99 [0.56, 1.77] | 1 study · 311 participants | Low |
Oxaliplatin vs the same regimen including cisplatin Overall Survival · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.81 [0.67, 0.98] | 5 studies · 1105 participants | Low |
Oxaliplatin vs the same regimen including cisplatin Tumour response · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 1.38 [1.08, 1.76] | 5 studies · 1081 participants | Moderate |